ACT completes $71B(!) AGN acquisition—adds two independent directors: http://finance.yahoo.com/news/actavis-completes-allergan-acquisition-125600951.html http://finance.yahoo.com/news/actavis-announces-michael-r-gallagher-131000312.html AGN’s CEO, David Pyott, will not join ACT’s BoD. Reminder: This was third-largest drug/biotech acquisition of all time!